COVID-19 SARS-CoV-2 Infection

Infectious Diseases
1
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
ibuzatrelvirPhase 3Small Molecule4 trials
Active Trials
NCT07235137Completed12Est. Nov 2025
NCT06679140Recruiting2,330Est. Mar 2028
NCT06693518Completed20Est. Jan 2025
+1 more trials

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
Pfizeribuzatrelvir
Pfizeribuzatrelvir
Pfizeribuzatrelvir
Pfizeribuzatrelvir

Clinical Trials (4)

Total enrollment: 2,374 patients across 4 trials

NCT06679140Pfizeribuzatrelvir

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Start: Dec 2024Est. completion: Mar 20282,330 patients
Phase 3Recruiting
NCT07235137Pfizeribuzatrelvir

A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults

Start: Oct 2025Est. completion: Nov 202512 patients
Phase 1Completed
NCT06693518Pfizeribuzatrelvir

A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults

Start: Nov 2024Est. completion: Jan 202520 patients
Phase 1Completed
NCT06646042Pfizeribuzatrelvir

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

Start: Oct 2024Est. completion: Jan 202512 patients
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 2,374 patients
1 companies competing in this space